Assembly Biosciences (NASDAQ:ASMB) Shares Cross Above 200-Day Moving Average of $11.40

Assembly Biosciences, Inc. (NASDAQ:ASMB) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $11.40 and traded as high as $15.45. Assembly Biosciences shares last traded at $14.85, with a volume of 23,471 shares changing hands.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ASMB shares. StockNews.com raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Friday, May 10th. HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a research report on Monday, April 1st.

Assembly Biosciences Price Performance

The company’s 50-day simple moving average is $13.48 and its 200-day simple moving average is $11.46.

Hedge Funds Weigh In On Assembly Biosciences

A hedge fund recently bought a new stake in Assembly Biosciences stock. Marquette Asset Management LLC acquired a new position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 54,464 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Marquette Asset Management LLC owned 0.08% of Assembly Biosciences as of its most recent SEC filing. Hedge funds and other institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.